

Supplementary figure 6: MCT-1 inhibition on CD19-CD28 CAR T cells. MCT-1 inhibitors were added to non-transduced or  $\alpha$ CD19-CAR T cells with a CD28 co-stimulatory domain. (A) Schematic of RQR8 and  $\alpha$ CD19-FMC63-CD28 CAR construct. (B) Percentage of live Raji cells cultured with CAR T cells at different effector: target ratios (E:T) ratios. (C) Relative MFI of 2-NBDG uptake. Expression of (D) 4-1BB and (E) CD69 re-stimulated CAR T cells with Raji cells or Raji-CD19<sup>KO</sup> (Resting CAR Ts) for 24 hours. (F) IFN- $\gamma$  and (G) IL-2 production measured by ELISA after 48 hours. Pooled data of two to three independent experiments, n=5-9 healthy donors per group. Bars are the mean  $\pm$  SD. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, ns=non-significant by Friedman One-Way

ANOVA.